ifenprodil has been researched along with Parkinson Disease in 6 studies
ifenprodil: NMDA receptor antagonist
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatments for Parkinson's disease based on replacement of lost dopamine have several problems." | 1.31 | Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. ( Brotchie, JM; Nash, JE, 2002) |
| "In animal models of Parkinson's disease, loss of striatal dopamine leads to enhanced excitation of striatal NR2B-containing NMDA receptors." | 1.31 | Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. ( Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Hill, MP; Hille, C; Maneuf, Y; McGuire, S; Nash, JE; Peggs, D, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Trippier, PC | 1 |
| Jansen Labby, K | 1 |
| Hawker, DD | 1 |
| Mataka, JJ | 1 |
| Silverman, RB | 1 |
| Nash, JE | 2 |
| Brotchie, JM | 2 |
| Kornhuber, J | 1 |
| Riederer, P | 1 |
| Montastruc, JL | 2 |
| Rascol, O | 2 |
| Senard, JM | 2 |
| Fox, SH | 1 |
| Henry, B | 1 |
| Hill, MP | 1 |
| Peggs, D | 1 |
| McGuire, S | 1 |
| Maneuf, Y | 1 |
| Hille, C | 1 |
| Crossman, AR | 1 |
| Rascol, A | 1 |
2 reviews available for ifenprodil and Parkinson Disease
| Article | Year |
|---|---|
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antioxidants; Calcium Channels; Drug Combinations; | 2013 |
Glutamate antagonists and Parkinson's disease: a review of clinical data.
Topics: Antiparkinson Agents; Dextromethorphan; Excitatory Amino Acid Antagonists; Humans; Parkinson Disease | 1997 |
4 other studies available for ifenprodil and Parkinson Disease
| Article | Year |
|---|---|
Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dopamine; Dose-Response Relationsh | 2002 |
N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease.
Topics: Adrenergic alpha-Antagonists; Humans; Parkinson Disease; Piperidines; Receptors, N-Methyl-D-Aspartat | 1993 |
Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Calli | 2000 |
A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease.
Topics: Aged; Antiparkinson Agents; Drug Therapy, Combination; Humans; Levodopa; Neurologic Examination; Par | 1992 |